Market Overview

GlaxoSmithKline's Phase 3 Malaria Vaccine Study Meets Primary Endpoint

Related AGEN
Positive Results on Intercept Pharma's OCA - Analyst Blog
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Glaxo Cancer Vaccine Fails, Testing Continues (Fox Business)

Agenus (NASDAQ: AGEN) today announced the second complete set of results from the Phase 3 trial of GlaxoSmithKline's (NYSE: GSK) RTS,S malaria vaccine candidate (also known as Mosquirixâ„¢), which contains Agenus' QS-21 Stimulon adjuvant, were published online in the New England Journal of Medicine and announced at the International Vaccines for Africa Conference in Cape Town, South Africa. QS-21 Stimulon is a component of AS01, one of GSK's proprietary adjuvant systems used in RTS,S.

In this trial, infants (aged 6-12 weeks at first vaccination) receiving the RTS,S vaccine candidate experienced one-third fewer episodes of both clinical and severe malaria and experienced similar reactions to the injection when compared to those who received the control meningococcal C conjugate vaccine. Insecticide-treated bed nets were used by 86% of the trial participants demonstrating that RTS,S provided protection beyond existing malaria control interventions.

The results of this trial are

See full press release

Posted-In: News Guidance Management Global

 

Most Popular

Related Articles (AGEN + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free